Assessment of the Long-term Safety and Efficacy of Erenumab During Open-label Treatment in Patients With Chronic Migraine

Stewart J. Tepper,1 Messoud Ashina,2 Uwe Reuter,3 Jan L. Brandes,4 David Doležil,5 Stephen Silberstein,6 Paul Winner,7 Feng Zhang,8 Sunfa Cheng,9 Daniel D. Mikol9

Introduction

• Erenumab, a fully human monoclonal antibody specific to the calcitonin-gene-related peptide (CGRP) receptor complex, is approved in the United States for prevention of episodic migraine and chronic migraine at subcutaneous doses of 70 mg or 140 mg monthly1
• The short-term efficacy and safety of erenumab in chronic migraine was confirmed in a pivotal 12-week, placebo-controlled study (NCT02066415)2
• The current study aimed to assess the long-term safety and efficacy data in chronic migraine over one year of open-label treatment with erenumab (NCT02174861)
Learn more about the clinical trial design Arrow

1Geisel School of Medicine at Dartmouth, Hanover, NH, USA; 2Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark; 3Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 4Nashville Neuroscience Group and Vanderbilt University Department of Neurology, Nashville, TN, USA; 5Dado Medical sro, Prague Headache Center, Prague, Czech Republic; 6Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA; 7Premiere Research Institute, Nova Southeastern University, West Palm Beach, FL, USA; 8Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA; 9Global Development, Amgen Inc., Thousand Oaks, CA, USA.